EF Hutton Maintains Hold on Rain Oncology, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler maintains a Hold rating on Rain Oncology (NASDAQ:RAIN) and lowers the price target from $5 to $2.
May 30, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
EF Hutton maintains a Hold rating on Rain Oncology and lowers the price target from $5 to $2.
The lowered price target from $5 to $2 by EF Hutton analyst Tony Butler indicates a bearish outlook on Rain Oncology's stock. This news is likely to have a negative impact on the stock price in the short term as it suggests that the analyst believes the stock is overvalued at its current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100